Myriad Genetics appoints Mark S. Davis to Board, expanding to nine members

MYRIAD GENETICS INC

Mark S. Davis appointed as Class I Director effective December 10, 2024, expanding Board from eight to nine.
Davis will serve on Audit and Finance Committee; deemed independent and an audit committee financial expert.
Received restricted stock unit award of $350,000 vesting one year from grant date.
Davis spent nearly 40 years at Deloitte & Touche LLP, last as National Managing Partner of Deloitte Private.
Also serves on boards of Yext, Inc., NYU-Winthrop Hospital, and Adelphi University.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.